GPCRs and cancer

Acta Pharmacologica Sinica

Volumn 33, Issue 3, 2012, Pages 351-362

  Lappano, Rosamaria ^a   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

cancer; G protein coupled receptors; heterotrimeric G proteins; hormones; lipids; peptides; signal transduction

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HORMONE; LIPID; NEUROTRANSMITTER; PEPTIDE DERIVATIVE;

HUMAN; METASTASIS; MULTIGENE FAMILY; NEOPLASM; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84858122979     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.183     Document Type: Review

References (182)

1. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50. (Pubitemid 34987785)
2. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-9. (Pubitemid 34579147)
3. Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009; 9: 15-23.
4. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004; 92: 913.
5. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nature Rev Cancer 2007; 7: 79-94. (Pubitemid 46164746)
6. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10: 47-60.
7. Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst 2010; 102: 1568-83.
8. Voisin T, El Firar A, Fasseu M, Rouyer-Fessard C, Descatoire V, Walker F, et al. Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. Cancer Res 2011; 71: 3341-51.
9. Almendro V, García-Recio S, Gascón P. Tyrosine kinase receptor transactivation associated to G protein-coupled receptors. Curr Drug Targets 2010; 11: 1169-80.
10. Luttrell LM. Location, location, location: activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinol 2003; 30: 117-26. (Pubitemid 36592506)
11. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-91.
12. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13: 653-68. (Pubitemid 34567371)
13. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-91. (Pubitemid 37328830)
14. Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett 2003; 192: 161-9. (Pubitemid 36369270)
15. Shida D, Watanabe T, Aoki J, Hama K, Kitayama J, Sonoda H. Aberrant expression of lysophosphatidic acid (LPA) receptors in human colorectal cancer. Lab Investigation 2004; 84: 1352-62. (Pubitemid 40063699)
16. Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, et al. Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2. Cancer Res 2007; 67: 11751-9.
17. Boucharaba A, Serre CM, Guglielmi J, Bordet JC, Clezardin P, Peyruchaud O. The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. Proc Natl Acad Sci U S A 2006; 103: 9643-8. (Pubitemid 43955878)
18. Kim JH, Adelstein RS. LPA(1)-induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells. J Cell Physiol 2011; 226: 2881-93.
19. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 2009; 15: 539-50.
20. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, et al. Lysophosphatidic acid stimulates ovarian cancer cell migration via a Ras-MEK kinase 1 pathway. Cancer Res 2004; 64: 4209-17. (Pubitemid 38802425)
21. Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med 2010; 49: 2058-67.
22. Chen H, Wu X, Pan ZK, Huang S. Integrity of SOS1/EPS8/ABI1 tricomplex determines ovarian cancer metastasis. Cancer Res 2010; 70: 9979-90.
23. Li H, Wang D, Zhang H, Kirmani K, Zhao Z, Steinmetz R, et al. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 2009; 8: 1692-701.
24. Oyesanya RA, Greenbaum S, Dang D, Lee Z, Mukherjee A, Wu J, et al. Differential requirement of the epidermal growth factor receptor for G protein-mediated activation of transcription factors by lysophosphatidic acid. Mol Cancer 2010; 9: 8.
25. Snider AJ, Zhang Z, Xie Y, Meier KE. Epidermal growth factor increases lysophosphatidic acid production in human ovarian cancer cells: roles for phospholipase D2 and receptor transactivation. Am J Physiol Cell Physiol 2010; 298: C163-70.
26. Jeon ES, Lee IH, Heo SC, Shin SH, Choi YJ, Park JH, et al. Mesenchymal stem cells stimulate angiogenesis in a murine xenograft model of A549 human adenocarcinoma through an LPA1 receptordependent mechanism. Biochim Biophys Acta 2010; 1801: 1205-13.
27. Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010; 116: 1739-50. 358 www.nature.com/aps
28. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer 2010; 10: 489-503.
29. Goetzl EJ, Dolezalova H, Kong Y, Zeng L. Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Cancer Res 1999; 59: 4732-7. (Pubitemid 29428984)
30. Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 2006; 130: 80-7. (Pubitemid 43028568)
31. Bergelin N, Löf C, Balthasar S, Kalhori V, Törnquist K. S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology 2010; 151: 2994-3005.
32. Lepley D, Paik JH, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res 2005; 65: 3788-95. (Pubitemid 40616357)
33. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med 2010; 16: 1421-8.
34. Li MH, Sanchez T, Yamase H, Hla T, Oo ML, Pappalardo A, et al. S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett 2009; 276: 171-9.
35. Young N, Pearl DK, Van Brocklyn JR. Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res 2009; 7: 23-32.
36. Arikawa K, Takuwa N, Yamaguchi H, Sugimoto N, Kitayama J, Nagawa H, et al. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity. J Biol Chem 2003; 278: 32841-51. (Pubitemid 37055726)
37. Takuwa Y, Du W, Qi X, Okamoto Y, Takuwa N, Yoshioka K. Roles of sphingosine-1-phosphate signaling in angiogenesis. World J Biol Chem 2010; 1: 298-306.
38. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 2006; 9: 225-38. (Pubitemid 43357948)
39. Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 2004; 114: 1082-9. (Pubitemid 39578697)
40. Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, Sugihara K, et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Cancer Res 2010; 70: 772-81.
41. Bagnato A, Rosanò L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008; 40: 1443-51.
42. Arun C, London NJ, Hemingway DM. Prognostic significance of elevated endothelin-1 levels in patients with colorectal cancer. Int J Biol Markers 2004; 19: 32-7. (Pubitemid 38515009)
43. Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163: 220-33.
44. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17: 2350-60.
45. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 2005; 7: 426-31. (Pubitemid 40664232)
46. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003; 22: 6183-93. (Pubitemid 37281648)
47. Hohla F, Schally AV. Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. Cell Cycle 2010; 9: 1738-41.
48. Mu L, Honer M, Becaud J, Martic M, Schubiger PA, Ametamey SM, et al. In vitro and in vivo characterization of novel 18F-labeled bombesin analogues for targeting GRPR-positive tumors. Bioconjug Chem 2010; 21: 1864-71.
49. Honer M, Mu L, Stellfeld T, Graham K, Martic M, Fischer CR, et al. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. J Nucl Med 2011; 52: 270-8.
50. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
51. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009; 69: 6223-31.
52. Wysoczynski M, Liu R, Kucia M, Drukala J, Ratajczak MZ. Thrombin regulates the metastatic potential of human rhabdomyosarcoma cells: distinct role of PAR1 and PAR3 signaling. Mol Cancer Res 2010; 8: 677-90.
53. García-López MT, Gutiérrez-Rodríguez M, Herranz R. Thrombinactivated receptors: promising targets for cancer therapy? Curr Med Chem 2010; 17: 109-28.
54. Arora P, Cuevas BD, Russo A, Johnson GL, Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 2008; 27: 4434-45.
55. Villares GJ, Zigler M, Dobroff AS, Wang H, Song R, Melnikova VO, et al. Protease activated receptor-1 inhibits the Maspin tumorsuppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A 2011; 108: 626-31.
56. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005; 120: 303-13. (Pubitemid 40222426)
57. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010; 70: 5880-90.
58. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-80.
59. Hu T, Li C. Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer 2010; 9: 236.
60. Jones KA, Kemp CR. Wnt-induced proteolytic targeting. Genes Dev 2008; 22: 3077-81.
61. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 2010; 184: 702-12.
62. Lai SL, Chien AJ, Moon RT. Wnt/Fz signaling and the cytoskeleton: potential roles in tumorigenesis. Cell Res 2009; 19: 532-45.
63. Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, et al. Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol 2011; 54: 288-99.
64. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011; 30: 4437-46.
65. Jin X, Jeon HY, Joo KM, Kim JK, Jin J, Kim SH, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011; 71: 3066-75.
66. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30: 303-12.
67. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010; 1805: 181-208.
68. Singh S, Wang Z, Liang Fei D, Black KE, Goetz JA, Tokhunts R, et al. Hedgehog-producing cancer cells respond to and require autocrine Hedgehog activity. Cancer Res 2011; 71: 4454-63.
69. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-40.
70. Tang T, Tang JY, Li D, Reich M, Callahan CA, Fu L, et al. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011; 17: 3378-87.
71. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71: 5057-61.
72. Dijkgraaf GJ, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res 2011; 71: 435-44.
73. Tao H, Jin Q, Koo DI, Liao X, Englund NP, Wang Y, et al. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem Biol 2011; 18: 432-7.
74. Mazumdar T, DeVecchio J, Shi T, Jones J, Agyeman A, Houghton JA. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res 2011; 71: 1092-102.
75. Desch P, Asslaber D, Kern D, Schnidar H, Mangelberger D, Alinger B, et al. Inhibition of GLI, but not Smoothened, induces apoptosis in chronic lymphocytic leukemia cells. Oncogene 2010; 29: 4885-95.
76. Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17: 388-99.
77. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-44.
78. Thelen M. Dancing to the tune of chemokines. Nat Immunol 2001; 2: 129-34. (Pubitemid 33707930)
79. Kamohara H, Takahashi M, Ishiko T, Ogawa M, Baba H. Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol 2007; 31: 627-32.
80. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004; 4: 540-50. (Pubitemid 38868623)
81. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, et al. Snail promotes CXCR2 ligand-dependent tumor progression in nonsmall cell lung carcinoma. Clin Cancer Res 2009; 15: 6820-9.
82. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z, et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027-37.
83. Xu J, Zhang C, He Y, Wu H, Wang Z, Song W, et al. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer 2011. doi: 10.1002/ ijc.26035.
84. Singh S, Nannuru KC, Sadanandam A, Varney ML, Singh RK. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 2009; 100: 1638-46.
85. Su H, Sobrino Najul EJ, Toth TA, Ng CM, Lelievre SA, Fred M, et al. Chemokine receptor CXCR4-mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis. Cancer Lett 2011; 307: 132-40.
86. Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res 2011; 71: 603-13.
87. Dessein AF, Stechly L, Jonckheere N, Dumont P, Monté D, Leteurtre E, et al. Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells. Cancer Res 2010; 70: 4644-54.
88. Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 1671-9.
89. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, et al. CXCR4 is a prognostic marker in acute myelogenous leukemia. Cancer Cell 2004; 6: 459-69.
90. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005; 23: 2744-53. (Pubitemid 46179464)
91. Konoplev S, Jorgensen JL, Thomas DA, Lin E, Burger J, Kantarjian HM, et al. Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia. Cancer 2011; 117: 4689-95.
92. Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood 2004; 104: 550-7. (Pubitemid 38900040)
93. Furusato B, Mohamed A, Uhlén M, Rhim JS. CXCR4 and cancer. Pathol Int 2010; 60: 497-505.
94. Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K, Umezawa K. Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochem Biophys Res Commun 2010; 403: 154-9.
95. Schutyser E, Su Y, Yu Y, Gouwy M, Zaja-Milatovic S, Van Damme J, et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw 2007; 18: 59-70. (Pubitemid 47262360)
96. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, et al. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alphadirected invasion of human basal cell carcinoma cells. Oncogene 2007; 26: 2491-501.
97. Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 2011; 9: 161-72.
98. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med 2006; 203: 2201-13. (Pubitemid 44352240)
99. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007; 104: 15735-40. (Pubitemid 350035369)
100. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008; 283: 4283-94.
101. Uemura H, Hoshino K, Kubota Y. Engagement of renin-angiotensin system in prostate cancer. Curr Cancer Drug Targets 2011; 11: 442-50.
102. Taub JS, Guo R, Leeb-Lundberg LM, Madden JF, Daaka Y. Bradykinin receptor subtype 1 expression and function in prostate cancer. Cancer Res 2003; 63: 2037-41. (Pubitemid 36538604)
103. Daaka Y. G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004; 2004: re2.
104. Metzger E, Müller JM, Ferrari S, Buettner R, Schüle R. A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 2003; 22: 270-80. (Pubitemid 36119433)
105. Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, et al. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J 2000; 19: 359-69. (Pubitemid 30072606)
106. Hoshino K, Ishiguro H, Teranishi JI, Yoshida SI, Umemura S, Kubota Y, et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate 2011; 71: 964-75.
107. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-9. (Pubitemid 41206635)
108. Lau ST, Leung PS. Role of the RAS in pancreatic cancer. Curr Cancer Drug Targets 2011; 11: 412-20.
109. Ino K, Shibata K, Yamamoto E, Kajiyama H, Nawa A, Mabuchi Y, et al. Role of the renin-angiotensin system in gynecologic cancers. Curr Cancer Drug Targets 2011; 11: 405-11.
110. Molina L, Matus CE, Astroza A, Pavicic F, Tapia E, Toledo C, et al. Stimulation of the bradykinin B(1) receptor induces the proliferation of estrogen-sensitive breast cancer cells and activates the ERK1/2 signaling pathway. Breast Cancer Res Treat 2009; 118: 499-510.
111. Lu DY, Leung YM, Huang SM, Wong KL. Bradykinin-induced cell migration and COX-2 production mediated by the bradykinin B1 receptor in glioma cells. J Cell Biochem 2010; 110: 141-50.
112. Guha S, Lunn JA, Santiskulvong C, Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 2003; 63: 2379-87. (Pubitemid 36605172)
113. Kisfalvi K, Rey O, Young SH, Sinnett-Smith J, Rozengurt E. Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology 2007; 148: 3246-57. (Pubitemid 46996971)
114. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/ insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010; 16: 2505-11.
115. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009; 69: 6539-45.
116. Dolley-Hitze T, Jouan F, Martin B, Mottier S, Edeline J, Moranne O, et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? Br J Cancer 2010; 103: 1698-705.
117. Arrieta O, Guevara P, Escobar E, Garcìa-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005; 92: 1247-52. (Pubitemid 40604399)
118. Kosugi M, Miyajima A, Kikuchi E, Horiguchi Y, Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006; 12: 2888-93.
119. Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, et al. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol 2011; 107: 1028-33.
120. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomized controlled trials. Lancet Oncol 2010; 11: 627-36.
121. Pommerville PJ, de Boer JG. GnRH antagonists in the treatment of advanced prostate cancer. Can J Urol 2010; 17: 5063-70.
122. Yu B, Ruman J, Christman G. The role of peripheral gonadotropinreleasing hormone receptors in female reproduction. Fertil Steril 2011; 95: 465-73.
123. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2001; 163: 623-9.
124. Gründker C, Günthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002; 146: 1-14. (Pubitemid 34126412)
125. Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin. Oncogene 2011; 30: 2964-74.
126. Ling Poon S, Lau MT, Hammond GL, Leung PC. Gonadotropinreleasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells. Endocrinology 2011; 152: 764-72.
127. Schubert A, Hawighorst T, Emons G, Gründker C. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triplenegative human breast cancer cells in vivo. Breast Cancer Res Treat 2011; 130: 783-90
128. Kraus S, Levy G, Hanoch T, Naor Z, Seger R. Gonadotropin releasing hormone induces apoptosis of prostate cancer cells: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signalregulated kinase pathways. Cancer Res 2004; 64: 5736-44. (Pubitemid 39095572)
129. Kim DK, Yang JS, Maiti K, Hwang JI, Kim K, Seen D, et al. A gonadotropin releasing hormone-II antagonist induces autophagy of prostate cancer cells. Cancer Res 2009; 69: 923-31.
130. Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2010; 2: 39-52.
131. Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone in oncology. Comb Chem High Throughput Screen 2006; 9: 163-70.
132. Szepeshazi K, Schally AV, Nagy A. Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs. Breast Cancer Res Treat 1999; 56: 267-76. (Pubitemid 29495657)
133. Grundker C, Volker P, Griesinger F, Ramaswamy A, Nagy A, Schally AV, et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice. Am J Obstet Gynecol 2002; 187: 528-37.
134. Chen GG, Zeng Q, Tse GM. Estrogen and its receptors in cancer. Med Res Rev 2008; 28: 954-74.
135. Maggiolini M, Picard D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J Endocrinol 2010; 204: 105-14.
136. Smith HO, Leslie KK, Singh M, Qualls CR, Revankar CM, Joste NE, et al. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am J Obstet Gynecol 2007; 196: 386.e1-9.
137. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, et al. GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009; 114: 465-71.
138. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, et al. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006; 12: 6359-66. (Pubitemid 44799705)
139. Prossnitz ER, Maggiolini M. Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 2009; 308: 32-8.
140. Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005; 146: 624-32. (Pubitemid 40129818)
141. Thomas P, Dong J. Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J Steroid Biochem Mol Biol 2006; 102: 175-9. (Pubitemid 44750643)
142. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein coupled receptor GPR30 mediates c-fos upregulation by 17β-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 2004; 279: 27008-16. (Pubitemid 38812536)
143. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 2006; 20: 631-46. (Pubitemid 43291214)
144. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-66. (Pubitemid 46383413)
145. Albanito L, Lappano R, Madeo A, Chimento A, Prossnitz ER, Cappello AR, et al. G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ Health Perspect 2008; 116: 1648-55.
146. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008; 149: 3799-808.
147. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009; 28: 523-32.
148. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, et al. G protein-coupled receptor 30 expression is upregulated by EGF and TGFalpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 2009; 11: 1815-26.
149. Lappano R, Rosano C, De Marco P, De Francesco EM, Pezzi V, Maggiolini M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol Cell Endocrinol 2010; 320: 162-70.
150. Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010; 70: 6036-46.
151. Schuller HM. Neurotransmission and cancer: implications for prevention and therapy. Anticancer Drugs 2008; 19: 655-71.
152. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006; 12: 939-44. (Pubitemid 44175146)
153. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 2009; 23: 267-75.
154. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010, 70: 7042-52.
155. Lutgendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Jabbari S, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res 2003; 9: 4514-21. (Pubitemid 37248410)
156. Lüthy IA, Bruzzone A, Piñero CP, Castillo LF, Chiesa IJ, Vázquez SM, et al. Adrenoceptors: non conventional target for breast cancer? Curr Med Chem 2009; 16: 1850-62.
157. Shah N, Khurana S, Cheng K, Raufman JP. Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol 2009; 296: C221-32.
158. De Sarno P, Shestopal SA, King TD, Zmijewska A, Song L, Jope RS. Muscarinic receptor activation protects cells from apoptotic effects of DNA damage, oxidative stress, and mitochondrial inhibition. J Biol Chem 2003; 278: 11086-93. (Pubitemid 36792660)
159. Oppitz M, Mobus V, Brock S, Drews U. Muscarinic receptors in cell lines from ovarian carcinoma: negative correlation with survival of patients. Gynecol
160. Kawashima K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol Ther 2000; 86: 29-48. (Pubitemid 30173143)
161. Español AJ, de la Torre E, Fiszman GL, Sales ME. Role of nonneuronal cholinergic system in breast cancer progression. Life Sci 2007; 80: 2281-5. (Pubitemid 46818254)
162. Cheng K, Zimniak P, Raufman JP. Transactivation of the epidermal growth factor receptor mediates cholinergic agonist-induced proliferation of H508 human colon cancer cells. Cancer Res 2003; 63: 6744-50. (Pubitemid 37322954)
163. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28: 836-46. (Pubitemid 32662546)
164. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 2002; 7: 91-8.
165. Sun LC, Coy DH. Somatostatin receptor-targeted anti-cancer therapy. Curr Drug Deliv 2011; 8: 2-10.
166. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115: 455-65. (Pubitemid 34182973)
167. Ribas C, Penela P, Murga C, Salcedo A, García-Hoz C, Jurado-Pueyo M, et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta 2007; 1768: 913-22. (Pubitemid 46452540)
168. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by betaarrestins. Science 2005; 308: 512-7.
169. Rakesh K, Yoo B, Kim IM, Salazar N, Kim KS, Rockman HA. beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci Signal 2010; 3: ra46.
170. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, et al. Beta-arrestin/Ral signaling regulates lysophosphatidic acidmediated migration and invasion of human breast tumor cells. Mol Cancer Res 2009; 7: 1064-77.
171. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006; 103: 1492-7. (Pubitemid 43191193)
172. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 2009; 106: 2806-11.
173. Zhang Y, Qian Y, Lu W, Chen X. The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 2009; 69: 6049-56.
174. Zhang Y, Scoumanne A, Chen X. G protein-coupled receptor 87: a promising opportunity for cancer drug discovery. Mol Cell Pharmacol 2010; 2: 111-6.
175. Jin Z, Luo R, Piao X. GPR56 and its related diseases. Prog Mol Biol Transl Sci 2009; 89: 1-13.
176. Tanese K, Fukuma M, Yamada T, Mori T, Yoshikawa T, Watanabe W, et al. G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol 2008; 173: 835-43.
177. Qin Y, Verdegaal EM, Siderius M, Bebelman JP, Smit MJ, Leurs R, et al. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target. Pigment Cell Melanoma Res 2011; 24: 207-18.
178. Gugger M, White R, Song S, Waser B, Cescato R, Rivière P, et al. GPR87 is an overexpressed G-protein coupled receptor in squamous cell carcinoma of the lung. Dis Markers 2008; 24: 41-50. (Pubitemid 350174569)
179. Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, Su KC, et al. hGPR87 contributes to viability of human tumor cells. Int J Cancer 2008; 122: 2008-16. (Pubitemid 351441189)
180. Tabata K, Baba K, Shiraishi A, Ito M, Fujita N. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007; 363: 861-6. (Pubitemid 47516713)
181. Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, et al. GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 2010; 27: 241-9.
182. Yang L, Chen G, Mohanty S, Scott G, Fazal F, Rahman A, et al. GPR56 Regulates VEGF production and angiogenesis during melanoma progression. Cancer Res 2011; 71: 5558-68.